Axsome Therapeutics Inc’s recent filing unveils that its Chief Financial Officer Pizzie Nick unloaded Company’s shares for reported $1.56 million on Feb 13 ’25. In the deal valued at $129.86 per share,12,000 shares were sold. As a result of this transaction, Pizzie Nick now holds 42,187 shares worth roughly $5.36 million.
Then, Pizzie Nick sold 3,000 shares, generating $393,210 in total proceeds. Upon selling the shares at $131.07, the Chief Financial Officer now owns 42,187 shares.
Before that, Pizzie Nick bought 3,000 shares. Axsome Therapeutics Inc shares valued at $393,202 were divested by the Officer at a price of $131.07 per share.
Deutsche Bank initiated its Axsome Therapeutics Inc [AXSM] rating to a Buy in a research note published on February 11, 2025; the price target was $176. A number of analysts have revised their coverage, including Mizuho’s analysts, who remained covering the stock and in late December has reiterated a ‘”an Outperform”‘ rating for it. Wells Fargo began covering AXSM with “an Overweight” recommendation on September 03, 2024. BofA Securities revised its rating on August 06, 2024. It rated AXSM as “a Buy” which previously was an “a Neutral”.
Price Performance Review of AXSM
On Tuesday, Axsome Therapeutics Inc [NASDAQ:AXSM] saw its stock fall -2.78% to $127.09. Over the last five days, the stock has lost -0.78%. Axsome Therapeutics Inc shares have risen nearly 50.21% since the year began. Nevertheless, the stocks have risen 57.93% over the past one year. While a 52-week high of $139.13 was reached on 02/21/25, a 52-week low of $64.11 was recorded on 01/10/25. SMA at 50 days reached $102.54, while 200 days put it at $90.30.
Levels Of Support And Resistance For AXSM Stock
The 24-hour chart illustrates a support level at 123.44, which if violated will result in even more drops to 119.80. On the upside, there is a resistance level at 131.36. A further resistance level may holdings at 135.64. The Relative Strength Index (RSI) on the 14-day chart is 60.16, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 5.95, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 35.81%. Stochastics %K at 78.42% indicates the stock is a holding.
The most recent change occurred on July 22, 2024 when Needham began covering the stock and recommended ‘”a Buy”‘ rating along with a $130 price target.